Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 37 of 6351
-
Veterans helping veterans: new study aims to stop suicide
Prevention Recruiting nowThis study examines a novel way to prevent suicide among Veterans with serious mental illness (SMI). It will assess the efficacy of PREVAIL-VA, a 3-month intervention of 12, one-on-one sessions between a Peer Specialist (PS) and a Veteran that involve semi-structured conversation…
Sponsor: VA Office of Research and Development • Aim: Prevention
Last updated Sep 10, 2026 00:00 UTC
-
Engineered immune cells aim to stop bone Cancer's return in kids
Disease control Recruiting nowThe purpose of this study is to assess the safety, feasibility, and effectiveness of a consolidative B7-H3 CAR T cell therapy in patients with newly diagnosed high-risk osteosarcoma who have undergone upfront standard chemotherapy. Primary Objectives: \- To evaluate 1-year RFS …
Phase 2 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Can a Two-Pronged radiation strategy boost immunotherapy against advanced nasopharyngeal cancer?
Disease control Not yet recruitingThe RADIANCE trial plans to enroll patients with chemotherapy-ineligible de novo metastatic nasopharyngeal carcinoma (AJCC 9th edition, TxNxM1). Participants will receive Radscopal radiotherapy, consisting of low-dose radiotherapy to the primary lesions and stereotactic body radi…
Phase 2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can a seizure drug outsmart a deadly brain tumor?
Disease control Not yet recruitingGlioblastoma (GBM) is the most common primary malignant brain tumor in adults and is associated with poor prognosis despite standard treatment with maximal safe resection followed by radiotherapy plus temozolomide (the Stupp regimen). Tumor hypoxia is associated with treatment re…
Phase 2 • Sponsor: Tianjin Medical University General Hospital • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can a drug combo make rectal cancer disappear before surgery?
Disease control Not yet recruitingThis study aims to observe and evaluate the efficacy and safety of Iparomlimab and Tuvonralimab(QL-1706) combined with chemotherapy and bevacizumab ± radiotherapy as neoadjuvant therapy in patients with locally advanced rectal cancer, and to explore the value and implications of …
Sponsor: Zhejiang University • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
A future without surgery for stomach and colon cancers?
Disease control Not yet recruitingThe NOMAD-GI study is a single-center, bidirectional cohort study designed to evaluate the safety and efficacy of molecular biomarker-guided non-operative management (NOM) and organ preservation strategies after precision therapy in patients with gastrointestinal cancers. Patien…
Sponsor: Peking University Cancer Hospital & Institute • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
Can a Four-Drug cocktail shield kidneys in diabetes?
Disease control Not yet recruitingThis study employs a prospective, randomized, double-blind, parallel-controlled design, aiming to enroll adult participants with type 2 diabetic kidney disease (DKD) who meet the eligibility criteria. With an angiotensin receptor blocker (ARB) as the background therapy, all parti…
Phase 4 • Sponsor: Huijie Zhang • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
Can a new injection help people shed significant weight?
Disease control Not yet recruitingThis is a phase 3, multicenter, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of MWN109 injection in non-diabetic participants with overweight or obesity. Approximately 760 participants will be enrolled. All participants will be …
Phase 3 • Sponsor: Shanghai Minwei Biotechnology Co., Ltd • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
Can matching drugs to biology beat ARDS?
Disease control Not yet recruitingThe goal of this trial is to accelerate the development of pharmacological therapies for critical illness by identifying biological sub phenotypes in patients with acute respiratory distress syndrome (ARDS). The trial will stratify participants by biological markers into differen…
Phase 2 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Can a Two-Drug combo outsmart Hard-to-Treat breast cancer?
Disease control Not yet recruitingThis is a multicenter, open-label, single-arm phase II clinical trial designed to evaluate the efficacy and safety of Sacituzumab govitecan (SG) in combination with Q901 in patients with advanced (metastatic/recurrent/unresectable) triple-negative breast cancer (TNBC) whose disea…
Phase 2 • Sponsor: Yonsei University • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Can engineered immune cells calm autoimmune blood disorders?
Disease control Not yet recruitingThis is a phase 1 study to evaluate the safety and tolerability of AZD0120 in patients with relapsed or refractory immune mediated cytopenia (primary chronic Immune Thrombocytopenia (ITP) or autoimmune hemolytic anemia (wAIHA)).
Phase 1 • Sponsor: Saurabh Dahiya • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
A drop of cord blood at birth could flag a rare condition that harms infant brains
Diagnosis Not yet recruitingCongenital hyperinsulinism (HI) causes persistent neonatal hypoglycemia that, if untreated, can lead to neurodevelopmental impairments (NDI) such as cognitive delays, cerebral palsy, epilepsy, and blindness. Despite being preventable with early diagnosis and treatment, 30-50% of …
Sponsor: Odense University Hospital • Aim: Diagnosis
Last updated Sep 02, 2026 00:00 UTC
-
A daily pill aims to stop overweight from turning into obesity and diabetes
Prevention Not yet recruitingThis study will evaluate the efficacy and safety of orforglipron in participants with overweight and assess whether it helps reduce the future risk of obesity-related conditions, including type 2 diabetes, hypertension, and dyslipidemia, and progression to class 1 obesity.
Phase 3 • Sponsor: Eli Lilly and Company • Aim: Prevention
Last updated Sep 02, 2026 00:00 UTC
-
Can a weekly shot ease sleep apnea and shed weight?
Disease control Not yet recruitingThis is a 56-week randomized, double blinded, parallel-controlled study evaluating the efficacy and safety of the HDM1005 in patients with obstructive sleep apnea (OSA) and obesity receiving positive airway pressure (PAP) therapy. Eligible participants will be screened and random…
Phase 3 • Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Can a Platinum-Free regimen beat nasopharyngeal carcinoma?
Disease control Not yet recruitingThis study aimed to investigate the efficacy of a platinum-free neoadjuvant regimen (gemcitabine, camrelizumab, endostar, and low-dose radiotherapy) followed by a risk-adapted therapeutic strategy in patients with locally advanced nasopharyngeal carcinoma. Specifically, the risk-…
Phase 2 • Sponsor: Zhejiang Cancer Hospital • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Can a new pill push hepatitis b virus to undetectable levels?
Disease control Not yet recruitingThis is a multicenter, randomized, double-blind, placebo-controlled Phase III study with an open-label extension. The purpose is to evaluate efficacy and safety in adult patients with chronic hepatitis B virus infection who have received at least 12 months of NAs therapy, to demo…
Phase 3 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Rare disease diagnoses could get faster as ontario tests wider access to genomic sequencing
Diagnosis Not yet recruitingGenomic sequencing (GS) is increasingly recommended as a diagnostic test for patients with suspected genetic disorders, but access often remains limited to those referred to medical geneticists. Enabling non-geneticist clinicians to access GS can expedite diagnoses for affected f…
Sponsor: The Hospital for Sick Children • Aim: Diagnosis
Last updated Sep 04, 2026 00:00 UTC
-
Can a Triple-Drug cholesterol blitz make heart plaques safer?
Disease control Not yet recruitingThis multicenter, randomized, open-label clinical trial will evaluate whether an early intensive lipid-lowering strategy can improve coronary plaque stabilization in patients hospitalized with acute coronary syndrome. A total of 294 participants will be randomly assigned in a 1:1…
Phase 4 • Sponsor: Seoul National University Bundang Hospital • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Can a pill combo keep uveal melanoma from coming back?
Disease control Recruiting nowThis is a randomized, multi-center, open-label study of adjuvant darovasertib in participants with non-metastatic uveal melanoma (OptimUM-11)
Phase 3 • Sponsor: IDEAYA Biosciences • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
A breath sniff could one day screen for lung cancer and more
Diagnosis Not yet recruitingThis prospective multicenter observational study will evaluate whether an electronic nose that analyzes patterns in exhaled breath can be developed as a noninvasive tool for early risk prescreening across several disease areas. The study will enroll up to 20,000 adults from hospi…
Sponsor: The First Affiliated Hospital of Guangzhou Medical University • Aim: Diagnosis
Last updated Sep 06, 2026 00:00 UTC